In the October edition of the Hardman Monthly newsletter, Chief Executive, Keith Hiscock analyses the much misunderstood – but highly important – issue of stock liquidity. In particular, he focuses on the lower echelons of the Main Market and of AIM.
02 Oct 2017
The Monthly October 2017
Time Finance plc (TIME:LON), 37.2 | Abzena (ABZA:LON), 0 | Advanced Oncotherapy Plc (AVO:LON), 1.9 | Allergy Therapeutics plc (AGY:LON), 2.8 | Alliance Pharma plc (APH:LON), 36.8 | Arbuthnot Banking Group PLC (ARBB:LON), 1,065 | Avacta Group PLC (AVCT:LON), 52.0 | Burford Capital Limited (BUR:LON), 1,129 | Chamberlin plc (CMH:LON), 1.7 | City of London Investment Group PLC (CLIG:LON), 318 | Evgen Pharma Plc (EVG:LON), 0 | Gateley (Holdings) Plc (GTLY:LON), 123 | Murgitroyd Group (MUR:LON), 0 | Woodbois Limited (WBI:LON), 0 | Cambridge Nutritional Sciences PLC (CNSL:LON), 3.2 | Primary Health Properties PLC (PHP:LON), 91.2 | R.E.A. Holdings plc (RE:LON), 70.2 | Scancell Holdings Plc (SCLP:LON), 10.2 | Sinclair Pharma (SPH:LON), 0 | Surface Transforms PLC (SCE:LON), 9.4 | Tissue Regenix Group plc (TRX:LON), 68.0 | Oxford BioMedica plc (OXB:LON), 188 | ValiRx PLC (VAL:LON), 3.8
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
The Monthly October 2017
Time Finance plc (TIME:LON), 37.2 | Abzena (ABZA:LON), 0 | Advanced Oncotherapy Plc (AVO:LON), 1.9 | Allergy Therapeutics plc (AGY:LON), 2.8 | Alliance Pharma plc (APH:LON), 36.8 | Arbuthnot Banking Group PLC (ARBB:LON), 1,065 | Avacta Group PLC (AVCT:LON), 52.0 | Burford Capital Limited (BUR:LON), 1,129 | Chamberlin plc (CMH:LON), 1.7 | City of London Investment Group PLC (CLIG:LON), 318 | Evgen Pharma Plc (EVG:LON), 0 | Gateley (Holdings) Plc (GTLY:LON), 123 | Murgitroyd Group (MUR:LON), 0 | Woodbois Limited (WBI:LON), 0 | Cambridge Nutritional Sciences PLC (CNSL:LON), 3.2 | Primary Health Properties PLC (PHP:LON), 91.2 | R.E.A. Holdings plc (RE:LON), 70.2 | Scancell Holdings Plc (SCLP:LON), 10.2 | Sinclair Pharma (SPH:LON), 0 | Surface Transforms PLC (SCE:LON), 9.4 | Tissue Regenix Group plc (TRX:LON), 68.0 | Oxford BioMedica plc (OXB:LON), 188 | ValiRx PLC (VAL:LON), 3.8
- Published:
02 Oct 2017 -
Author:
Mark Thomas -
Pages:
48
In the October edition of the Hardman Monthly newsletter, Chief Executive, Keith Hiscock analyses the much misunderstood – but highly important – issue of stock liquidity. In particular, he focuses on the lower echelons of the Main Market and of AIM.